Studio finanziato dalla Brain Research Foundation Verona.
Articolo pubblicato online il 26 ottobre 2017: https://link.springer.com/article/10.1007/s11060-017-2639-x
© Springer Science+Business Media, LLC 2017.
Alessandra Santangelo, Pietro Imbrucè, Beatrice Gardenghi, Laura Belli, Rina Agushi, Anna Tamanini, Silvia Munari, Alessandra Maria Bossi, Ilaria Scambi, Donatella Benati, Raffaella Mariotti, Gianfranco Di Gennaro, Andrea Sbarbati, Albino Eccher, Giuseppe Kenneth Ricciardi, Elisa Maria Ciceri, Francesco Sala, Giampietro Pinna, Giuseppe Lippi, Giulio Cabrini, Maria Cristina Dechecchi.
Malignant gliomas, the most frequent primary brain tumors, are characterized by a dismal prognosis. Reliable biomarkers complementary to neuroradiology in the differential diagnosis of gliomas and monitoring for postsurgical progression are unmet needs. Altered expression of several microRNAs in tumour tissues from patients with gliomas compared to normal brain tissue have been described, thus supporting the rationale of using microRNA-based biomarkers. Although different circulating microRNAs were proposed in association with gliomas, they have not been introduced into clinical practice so far. Blood samples were
collected from patients with high and low grade gliomas, both before and after surgical resection, and the expression of miR-21, miR-222 and miR-124-3p was measured in exosomes isolated from serum. The expression levels of miR-21, miR-222 and miR-124-3p in serum exosomes of patients with high grade gliomas were significantly higher than those of low grade gliomas and healthy controls and were sharply decreased in samples obtained after surgery. The analysis of miR-21, miR-222 and miR-124-3p in serum exosomes of patients affected by gliomas can provide a minimally invasive and innovative tool to help the differential
diagnosis of gliomas at their onset in the brain and predict glioma grading and non glial metastases before surgery.
Responsabile: Maria Cristina Dechecchi – AOVR